Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Single-cell transcriptomic studies reveal altered heterogeneity in CD41 enriched megakaryocytes after targeted therapy in myeloproliferative neoplasm

View Full Paper
Ask AI
Bookmark
Share

Authors

ASA SchildJWJeremy Q. WenJCJohn D. Crispino

Discussion

Loading...

Member takes

Overview

Single-cell RNA sequencing reveals changes in megakaryocyte populations and impaired hematopoiesis in myeloproliferative neoplasm, indicating potential therapeutic targets.

Key Points

  • This research focuses on the heterogeneity of megakaryocytes in myeloproliferative neoplasm after targeted therapy.
  • Used single-cell RNA sequencing on enriched megakaryocytes from animal models of myeloproliferative neoplasms.
  • Isolated cells from bone marrow by sorting for CD41+ populations and lineage depletion.
  • Compared megakaryocyte populations between WT and JAK2V617F mice post-transplant and after ruxolitinib treatment.
  • Identified heterogeneity in megakaryocyte populations based on gene expression profiles in myeloproliferative neoplasm models.
  • Observed an 8-fold increase in platelet populations in JAK2V617F mice; subsequent impacts on erythropoiesis noted.
  • Ruxolitinib treatment significantly reduced erythroid progenitor and platelet populations, correlating with anemia and thrombocytopenia.

Cite This Study

Schild et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0cehttps://doi.org/10.1182/blood-2025-3764
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single cell transcriptional profiling reveals distinct subsets of human megakaryocytes in myelofibrosis2025
  2. 2Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms2026 · 1 citations
  3. 3Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms2025
  4. 4Liposomal melatonin targets mutant hematopoiesis and bone marrow remodeling in MPN2025
  5. 5Unravelling molecular determinants of ruxolitinib treatment response in myelofibrosis using single cell multiomics2025 · 1 citations